Hosted on MSN11mon
JP Morgan upgrades Beam to overweight, cites AATD therapy potential
JP Morgan upgraded Beam Therapeutics (NASDAQ:BEAM) to overweight, citing the potential of its AATD treatment candidate BEAM-302. The investment bank there is now an expectation that AATD will be a ...
Beam upgraded by Bernstein ahead of AATD data
Bernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company ...
blueskynews4d
ELITE Simulations installs ELITE S812 FNPT II/AATD at Skyborne Airline Academy to support US expansion
Skyborne Airline Academy, known for its commitment to providing world-class pilot training, selected the ELITE S812 FNPT II/AATD for its unparalleled realism, versatility, and advanced features. The ...
Seeking Alpha13d
Beam upgraded by Bernstein ahead of AATD data
Bernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company’s drug candidate for alpha-1 antitrypsin deficiency, or AATD.